Relaxin and fibrosis: Emerging targets, challenges, and future directions

Area of Science:

• Biochemistry
• Pharmacology
• Cell Biology

Background:

• Relaxin is a peptide hormone recognized for its anti-fibrotic effects in various organs, primarily demonstrated in animal models.
• Serelaxin, a form of recombinant human relaxin, functions via the relaxin family peptide receptor 1 (RXFP1).
• It inhibits excessive extracellular matrix production (fibrosis) and reduces established scarring by promoting extracellular matrix degradation.

Purpose of the Study:

• To review newly identified tissue targets for serelaxin therapy in fibrotic diseases.
• To discuss the limitations and challenges in current serelaxin research.
• To build upon previous work detailing serelaxin's mechanisms in extracellular matrix remodeling.

Main Methods:

• Literature review focusing on recent studies of serelaxin's effects on fibrosis.
• Analysis of signaling pathways involved in extracellular matrix remodeling by serelaxin.
• Identification and discussion of novel tissue targets for serelaxin treatment.

Main Results:

• Serelaxin consistently inhibits fibrosis at multiple levels by targeting excessive extracellular matrix production.
• Serelaxin promotes the degradation of aberrant extracellular matrix components, thereby reducing established scarring.
• New tissue targets for serelaxin therapy in fibrotic conditions have been identified.

Conclusions:

• Serelaxin demonstrates significant potential as an anti-fibrotic therapeutic agent.
• Further research is needed to fully understand and overcome the limitations in serelaxin research.
• Targeting specific tissues may enhance the efficacy of serelaxin therapy for fibrosis.